BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26829596)

  • 1. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
    Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
    Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
    Lesche D; Sigurdardottir V; Setoud R; Oberhänsli M; Carrel T; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
    Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
    Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
    Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.
    Almeida-Paulo GN; Dapía García I; Lubomirov R; Borobia AM; Alonso-Sánchez NL; Espinosa L; Carcas-Sansuán AJ
    Pharmacogenomics J; 2018 Jan; 18(1):180-186. PubMed ID: 28094348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations.
    Pallet N; Jannot AS; El Bahri M; Etienne I; Buchler M; de Ligny BH; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Le Meur Y; Heng AE; Subra JF; Legendre C; Beaune P; Alberti C; Loriot MA; Thervet E
    Am J Transplant; 2015 Mar; 15(3):800-5. PubMed ID: 25588704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.